Please use this identifier to cite or link to this item: http://elea.unisa.it:8080/xmlui/handle/10556/1652
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorSenatore, C.-
dc.contributor.advisorCharlier, B.-
dc.contributor.advisorTruono, A.-
dc.contributor.advisorPunzi, R.-
dc.contributor.advisorD’Aniello, F.-
dc.contributor.advisorBoffa, N.-
dc.contributor.advisorIzzo, Viviana-
dc.contributor.advisorConti, Valeria-
dc.contributor.advisorRussomanno, Giusy-
dc.contributor.advisorManzo, V.-
dc.contributor.advisorFilippelli, Amelia-
dc.contributor.advisorMazzeo M, M.-
dc.date.accessioned2015-01-29T14:09:18Z-
dc.date.available2015-01-29T14:09:18Z-
dc.date.issued2015-
dc.identifier.citationSenatore C, Charlier B, Truono A, Punzi R, D’Aniello F, Boffa N, Izzo V, Conti V, Russomanno G, Manzo V, Filippelli A, Mazzeo M. A Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salerno. Translational Medicine @ UniSa 2015, 11(10):55-58en_US
dc.identifier.issn2239-9747en_US
dc.identifier.urihttp://hdl.handle.net/10556/1652-
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-456-
dc.description.abstractAbacavir is a nucleoside reverse transcriptase inhibitor largely used as part of the antiretroviral therapy in Human Immunodeficiency Virus (HIV)-infected patients. Some individuals (2-9%) who start an abacavir treatment show an immunologic reaction indicated as hypersensitivity reaction syndrome (HSR) that is often responsible for therapy discontinuation and could represent a life-threatening event. Some studies demonstrated a correlation between this adverse reaction and the class I of the major histocompatibility complex (MHC) allele, HLA-B*57.01, in several populations, including Caucasians. Nowadays, International HIV treatment guidelines recommend the HLA-B*57.01 genotyping before abacavir administration to reduce the incidence of HSR. Both male and female HIV-infected patients were enrolled at the Infectious Diseases Division at the University Hospital of Salerno, and admitted to a prospective HLA-B*57.01 screening. Genetic analysis was carried out through two sequential Real-Time PCR reactions in which Sybr-Green was used. Out of 248 patients, 215 were Italians from Southern Italy and 33 were coming from several non-EU members countries. All were genotyped: 6 Italians (2.8%) and 1 of the non-EU group (3%) were identified as HLA-B*57.01 carriers. In this paper we present our experience in the field of abacavir pharmacogenetic and confirm the importance of Real Time PCR as a valid and cost-effective HLA-B*57.01 typing methodology.en_US
dc.format.extentP. 55-58en_US
dc.language.isoenen_US
dc.sourceUniSa. Sistema Bibliotecario di Ateneoen_US
dc.subjectAbacaviren_US
dc.subjectHIVen_US
dc.subjectHLA-B*57.01en_US
dc.subjectHypersensitivity reactionen_US
dc.subjectReal-Time PCRen_US
dc.titleA Prospective Screening of HLA-B*57.01 Allelic Variant for Preventing the Hypersensivity Reaction to Abacavir: Experience from the Laboratory of Molecular Biology of the Infectious Diseases Division at the University Hospital of Salernoen_US
dc.typeArticleen_US
Appears in Collections:Translational Medicine @ UniSa. Volume 11 (jan.-apr. 2015)



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.